Eisai plots new drug applications in US, Europe and China after Lenvima scores in head-to-head liver cancer study
Eisai says that its cancer drug Lenvima (lenvatinib) hit the primary endpoint in a Phase III study for first-line use against liver cancer, proving non-inferior to Nexavar. That success, the company adds, will set up regulatory filings in the US, Europe and Asia.
Already approved for kidney cancer, Tokyo-based Eisai says their drug scored on the overall survival rate, testing it in a study with 954 patients. And investigators added that the drug also hit on a slate of secondary endpoints including progress-free survival, time to progression and the objective response rate.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.